Wells Fargo & Company Cuts Avantor (NYSE:AVTR) Price Target to $25.00

Avantor (NYSE:AVTR) had its price objective reduced by Wells Fargo & Company from $28.00 to $25.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts have also recently weighed in on AVTR. Raymond James dropped their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. UBS Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Robert W. Baird dropped their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Stifel Nicolaus dropped their price objective on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. Finally, Barclays dropped their target price on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research report on Monday. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Stock Performance

Shares of AVTR stock opened at $18.06 on Monday. The company has a market capitalization of $12.29 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 3.87 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a 50-day simple moving average of $21.63 and a 200 day simple moving average of $23.39. Avantor has a 52 week low of $18.00 and a 52 week high of $28.00.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the prior year, the business posted $0.22 earnings per share. On average, sell-side analysts predict that Avantor will post 0.98 earnings per share for the current year.

Hedge Funds Weigh In On Avantor

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Avantor by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 63,969,754 shares of the company’s stock worth $1,347,843,000 after purchasing an additional 1,211,418 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its position in Avantor by 41.4% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 30,528,092 shares of the company’s stock worth $643,227,000 after purchasing an additional 8,936,879 shares in the last quarter. State Street Corp increased its position in Avantor by 58.0% during the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after purchasing an additional 8,206,695 shares in the last quarter. Janus Henderson Group PLC increased its position in Avantor by 18.2% during the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock worth $457,710,000 after purchasing an additional 2,719,615 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Avantor by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 11,232,329 shares of the company’s stock worth $236,227,000 after purchasing an additional 81,541 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.